JS Bin

Scientific Advisory Board

is Professor of Human Nutrition and of Chemistry and Chemical Biology in the Division of Nutritional Sciences at Cornell University, Ithaca, New York, USA. He is also a member of Cornell’s graduate faculties of Food Science and Technology, and of Geological Sciences, and is Adjunct Professor in the Dept. of Community and Preventative Medicine at the University of Rochester (NY) Medical College. His research group focuses on study of polyunsaturated fatty acid (PUFA) nutrition in the perinatal period, and their role in neural and retinal development. Their studies of the efficacy of highly unsaturated PUFA as structural components of the central nervous system have helped to define the mechanism by which these fats support optimal visual and neural function. He has developed tracer methods based on stable isotopes and uses them extensively in metabolic studies. His group is also active in the development and application of biomedical molecular, elemental, and isotopic mass spectrometry, and in the use of high precision isotope ratio mass spectrometry for detection of endogenous steroid doping. The National Institutes of Health (NIH) has supported his research continuously since 1991 for these and related studies, as have numerous private companies.

is Professor and Chair, Chemical Kinetics, Moscow State University. Head of the Department of Dynamics of Chemical and Biological Processes, NN Semyonov Institute of Chemical Physics RAS. Member (1987) of the RAS (Head of the Chemical Kinetics Division). His interests include spin chemistry, stable radicals, physics of chemical reactions, radiospectroscopy, molecular ferromagnets, magnetic isotope effect in biology, isotope separation and nanotechnology. He discovered the magnetic isotope effect (1976) and chemically induced radio-frequency emission of chemical reactions. His plentiful awards include the USSR State Prize (1977) and the Lenin State Prize (1987). He has co-authored 8 books (including New Isotopy in Chemistry and Biochemistry, 2007), more than 300 per-reviewed papers, and several patents. He received his BA from Nizhny Novgorod State University in 1958.

is a member of the US National Academy of Sciences (1988) and is currently on leave from Boston University (Professor of Biomedical Engineering and Director of the Center for Advanced Biotechnology). Founder and CSO (since 1998) of Sequenom, Inc. His main areas of expertise: biophysics, molecular genetics, molecular biology, genomics, bioinformatics. His scientific interests include mass-spectrometry, prenatal diagnostics, in vivo RNA detection and epigenetics. He made important contributions to understanding of DNA-protein interactions and pioneered physical mapping of whole chromosomes. Invented (1984) and developed pulse field gel electrophoresis for analysis of very large DNA molecules. He is also founder of SelectX Pharmaceuticals and DiThera. His copious awards include Eli Lilly Award in Biological Chemistry (1978), Biochemical Analysis Prize of the German Society of Clinical Chemistry (1988), ISCO Award for Advances in Biochemical Instrumentation (1989), H.A. Sober Award (American Society for Biochemistry and Molecular Biology, 1990), and E.M. Gray Award (Biophysical Society, 2000). (Co)authored several books (including the 3-volume textbook, Biophysical Chemistry) and more than 450 per-reviewed papers, as well as more than 60 patents. He received his BA from Columbia University in 1963 and a Ph.D. from the University of California, Berkeley in 1966.

discovered that the low oxygen microenvironment of solid tumors acted as a selective pressure for the expansion of tumor cell variants that were highly aggressive due to the loss of the p53 and PTEN tumor suppressor genes. These highly cited studies provide insight into the role of the tumor microenvironment on tumor evolution, and why solid tumors are resistant to chemotherapy and radiotherapy. In 2006, he was named the Jack, Lulu and Sam Willson Professor of Cancer Biology. Amato is currently the Director of the Interdisciplinary Cancer Biology Research Program at Stanford and is the Director of the Division of Radiation and Cancer Biology. He also heads the Radiation Biology Program in Stanford’s Cancer Center. Established that lysyl oxidase is essential for the metastatic spread of tumor cells. LOX represents a new therapeutic target for the prevention and control of metastases. Dr. Giaccia is the principal investigator of an NIH Program Project Grant that is based on developing new strategies to exploit the tumor microenvironment. Has co-authored the sixth edition of the most prominent textbook in the field, “Radiation Biology for the Radiologist”, with Eric Hall from Columbia University. Published almost 200 peer reviewed articles, book chapters and reviews and is inventor on 6 patents. Dr. Giaccia was awarded an American Cancer Society Junior Faculty Research Award, Howard Hughes Junior faculty Award and the Michael Fry Award from the Radiation Research Society for his outstanding contributions on understanding the molecular mechanisms of resistance promoted by the tumor microenvironment. Dr. Giaccia earned his undergraduate degree from Lafayette College and his Ph.D. from the University of Pennsylvania. He completed a postdoctoral fellowship with Dr. Martin Brown at Stanford University.

main areas of scientific interest are bioinformatics, molecular and cellular biology, aging, gerontology and rejuvenation. More specifically, his focus is on the role and etiology of all the accumulating and eventually pathogenic molecular and cellular side-effects of metabolism that constitute mammalian aging; the design of interventions to reverse and/or obviate this accumulation. Dr. de Grey is the Founder and Chairman and CSO of the Methuselah Foundation. Proposed Mitochondrial Free Radical Theory of Aging (1999) and Strategies for Engineered Negligible Senescence (SENS, 2000-2005). Editor-in-Chief of Rejuvenation Research. His awards include the World Transhumanist Association HG Wells Award. He has co-authored two books (including Ending Aging, 2007) and more than 30 per-reviewed papers. Dr. de Grey received his Ph.D. from Cambridge University in 2000.

is director of the University of California San Diego Mitochondrial Disease Laboratory and Co-Director of the UCSD Mitochondrial and Metabolic Disease Center. He is the founding President of the Mitochondrial Medicine Society. Trained as a Pediatric Neurologist with a research interest in mitochondrial and metabolic diseases Dr. Haas is an active clinician involved with the care of patients of all ages with mitochondrial disease as well as clinical treatment trials in this population. His laboratory has focused on the diagnosis and treatment of mitochondrial disease with the development and application of miniaturized techniques for diagnosis and the study of potential treatments. Work with Parkinson disease mitochondria lead to confirmation of a mitochondrial defect and treatment trials with coenzyme Q10. Other research has included the development of sophisticated techniques for mitochondrial DNA analysis and the use of a DHPLC technique to study treatments in mitochondrial disease cells. Working with a committee of the Mitochondrial Medicine Society Dr. Haas recently authored articles on the diagnosis and treatment of mitochondrial disease for family practitioners and more detailed articles for geneticists and specialists. Recent research has included clinical and laboratory research on mitochondrial autism and the use of fibroblast skin cells for mitochondrial diagnosis.

After stints in the USA, Zimbabwe, and Ireland he took up a faculty position in the Biochemistry Department at the University of Otago, Dunedin, New Zealand in 1992. In 2001 he moved to the MRC Mitochondrial Biology Unit in Cambridge, UK (then called the MRC Dunn Human Nutrition Unit) where he is a group leader. His research is concerned with all aspects of mitochondrial function and dysfunction. Currently his special interests are in targeting small molecules such as antioxidants to mitochondria, and in understanding how modifications to the thiol status of mitochondrial proteins contributes to oxidative damage and redox signaling. Dr. Murphy received his BA in chemistry at Trinity College, Dublin in 1984 and his PhD in Biochemistry at Cambridge University in 1987.

As a leading researcher in angiogenesis and vascular cell biology, Prof. David Shima and collaborators performed pioneering studies in the early 1990s that elucidated the role of vascular endothelial growth factor (VEGF) during pathological neovascularization within the eye. Dr Shima's subsequent research efforts have provided important mechanistic insight into the varied roles of VEGF in blood vessel formation, neural cell development and neovascular disease. His investigations of intercellular communication within the cardiovasculature have also resulted in the identification and characterization of novel components of the vascular machinery, which represent potential targets for clinical intervention. Dr Shima joined Eyetech Pharmaceuticals, Inc. in 2002 to establish and oversee research and pipeline initiatives, and currently he heads the (OSI) Eyetech Research Center. Before joining Eyetech, he was the head of the Endothelial Cell Biology Laboratory at the Imperial Cancer Research Fund in London, England, where he also completed his postdoctoral training in membrane biology and biochemistry. Dr Shima received his Ph.D. in 1995 from the Program in Cell and Developmental Biology at Harvard University.

is Professor and Chair, Department of Genetics; Lola and Saul Kramer Chair in Molecular Genetics; Albert Einstein College of Medicine of Yeshiva University, NY. He moved from Europe to the USA in 1993 and held professorial positions at Harvard and University of Texas, San Antonio, and the Buck Institute for Age research (Novato, CA; 2006-2008). His areas of expertise include molecular genetics, gerontology, cancer and aging. More specifically, he is interested in damage (including oxidative damage) to the genome, genome instability and its role in the etiology of aging and age related disease. He was the first to develop transgenic mouse models (MutaMouse™) for studying mutagenesis in vivo (1989). He also demonstrated that the frequency of mutations increases with age in most tissues. Has been involved with biotech companies since 1990 (founded and directed Ingeny B.V. from 1990-1993). His many awards include the N. Shock New Investigator Award (The Gerontological Society of America, 1994) and the Ellison Medical Foundation Senior Scholar Award. He has co-authored several books (including Aging of the Genome, 2007), more than 200 peer-reviewed papers, and 8 patents. Dr. Vijg received his BS, MSc, Ph.D. (the University of Leiden, The Netherlands, 1987).